DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced consolidated results for the first quarter of 2008. First quarter 2008 revenues were $1.8 million compared to $1.7 million for the first quarter of 2007. Operating expenses decreased to $1.4 million for the first quarter of 2008 from $1.6 million for the first quarter of 2007. In addition, Neoprobe reported a net loss of $1.0 million or $0.02 per share for the quarter compared to a loss of $1.1 million or $0.02 per share for the comparable period in 2007. Neoprobe’s Loss from Operations for the first quarter of 2008 was $316,000 compared to $693,000 for the first quarter of 2007.
